US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Cellectis Inc.

< Previous 1 2 3 Next >
News headline image
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Announces Participation in Upcoming Investor Conferences
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Financial Results for the Second Quarter 2026
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Report Second Quarter Financial Results on August 6, 2026
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Financial Results for the First Quarter 2026
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Report First Quarter Financial Results on May 11, 2026
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Announces 2026 Strategy and Catalysts
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Announces Arbitral Decision in Dispute with Servier
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Present a Development Update for eti-cel at ASH 2025
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Report Third Quarter Financial Results on November 7, 2025
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Financial Results for the First Quarter 2025
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
< Previous 1 2 3 Next >